Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)

e.g. "Sirolimus", "アダリムマブ", "MAP2K"

ABCDEFGH I JKLMNOPQRSTUVWXYZother

134 / 286 pathways

No. KEGG PATHWAY   💬 Info on mouse-over
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES
💬 Info on mouse-over
KEGG DRUG
💬 Info on mouse-over
DrugBank 指定難病告示番号
💬 Info on mouse-over
1 Acute myeloid leukemia 💬
1件: KIT 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
2 Acute myeloid leukemia 💬
1件: KIT 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
3 Acute myeloid leukemia 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
4 Acute myeloid leukemia 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
5 Acute myeloid leukemia 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
6 Adherens junction 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
7 Adherens junction 💬
1件: FGFR1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
8 Adherens junction 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
9 Adipocytokine signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
10 Adipocytokine signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
11 Adipocytokine signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
12 Adrenergic signaling in cardiomyocytes 💬
1件: ADRB2 💬 D02147 💬 Salbutamol 14件: 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
13 AGE-RAGE signaling pathway in diabetic complications 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
14 Alanine, aspartate and glutamate metabolism 💬
4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
15 Aldosterone synthesis and secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
16 Alzheimer disease 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
17 Alzheimer disease 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
18 Alzheimer disease 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
19 Alzheimer disease 💬
1件: PTGS2 💬 D00567 💬 Celecoxib 9件: 2, 3, 34, 46, 70, 89, 161, 171, 271 💬
20 AMPK signaling pathway 💬
1件: HMGCR 💬 D00434 💬 Simvastatin 21件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
21 AMPK signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
22 AMPK signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
23 AMPK signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
24 Amyotrophic lateral sclerosis 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
25 Amyotrophic lateral sclerosis 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
26 Amyotrophic lateral sclerosis 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
27 Apelin signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
28 Apelin signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
29 Apelin signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
30 Arachidonic acid metabolism 💬
1件: PTGS2 💬 D00567 💬 Celecoxib 9件: 2, 3, 34, 46, 70, 89, 161, 171, 271 💬
31 Autophagy - animal 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
32 Autophagy - animal 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
33 Autophagy - animal 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
34 Autophagy - other 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
35 Autophagy - other 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
36 Autophagy - other 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
37 Axon guidance 💬
1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
38 Axon guidance 💬
1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
39 Axon guidance 💬
2件: ABL1, SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
40 Bacterial invasion of epithelial cells 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
41 beta-Alanine metabolism 💬
3件: ABAT, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
42 Bile secretion 💬
1件: HMGCR 💬 D00434 💬 Simvastatin 21件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
43 Bladder cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
44 Bladder cancer 💬
1件: FGFR3 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
45 Bladder cancer 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
46 Bladder cancer 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
47 Breast cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
48 Breast cancer 💬
2件: FGFR1, FLT4 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
49 Breast cancer 💬
1件: KIT 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
50 Breast cancer 💬
1件: KIT 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
51 Breast cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
52 Breast cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
53 Breast cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
54 Butanoate metabolism 💬
4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
55 C-type lectin receptor signaling pathway 💬
1件: PTGS2 💬 D00567 💬 Celecoxib 9件: 2, 3, 34, 46, 70, 89, 161, 171, 271 💬
56 C-type lectin receptor signaling pathway 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
57 Calcium signaling pathway 💬
1件: ADRB2 💬 D02147 💬 Salbutamol 14件: 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
58 Calcium signaling pathway 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
59 Calcium signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
60 Calcium signaling pathway 💬
8件: FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
61 Calcium signaling pathway 💬
1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
62 Calcium signaling pathway 💬
1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
63 Calcium signaling pathway 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
64 cAMP signaling pathway 💬
1件: ADRB2 💬 D02147 💬 Salbutamol 14件: 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
65 cAMP signaling pathway 💬
1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
66 cAMP signaling pathway 💬
1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
67 Cell cycle 💬
1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
68 Cell cycle 💬
1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
69 Cell cycle 💬
1件: ABL1 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
70 Cellular senescence 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
71 Cellular senescence 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
72 Cellular senescence 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
73 Central carbon metabolism in cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
74 Central carbon metabolism in cancer 💬
5件: FGFR1, FGFR2, FGFR3, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
75 Central carbon metabolism in cancer 💬
2件: KIT, PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
76 Central carbon metabolism in cancer 💬
2件: KIT, PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
77 Central carbon metabolism in cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
78 Central carbon metabolism in cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
79 Central carbon metabolism in cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
80 cGMP-PKG signaling pathway 💬
1件: ADRB2 💬 D02147 💬 Salbutamol 14件: 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299 💬
81 Chemical carcinogenesis 💬
1件: PTGS2 💬 D00567 💬 Celecoxib 9件: 2, 3, 34, 46, 70, 89, 161, 171, 271 💬
82 Chemokine signaling pathway 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
83 Choline metabolism in cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
84 Choline metabolism in cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
85 Choline metabolism in cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
86 Choline metabolism in cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
87 Choline metabolism in cancer 💬
1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
88 Choline metabolism in cancer 💬
1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
89 Choline metabolism in cancer 💬
2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
90 Chronic myeloid leukemia 💬
1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
91 Chronic myeloid leukemia 💬
1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
92 Chronic myeloid leukemia 💬
1件: ABL1 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
93 Circadian entrainment 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
94 Colorectal cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
95 Colorectal cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
96 Colorectal cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
97 Colorectal cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
98 Coronavirus disease - COVID-19 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
99 Cortisol synthesis and secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
100 Cushing syndrome 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
101 Cushing syndrome 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
102 Diabetic cardiomyopathy 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
103 Diabetic cardiomyopathy 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
104 Diabetic cardiomyopathy 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
105 EGFR tyrosine kinase inhibitor resistance 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
106 EGFR tyrosine kinase inhibitor resistance 💬
5件: FGFR2, FGFR3, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
107 EGFR tyrosine kinase inhibitor resistance 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
108 EGFR tyrosine kinase inhibitor resistance 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
109 EGFR tyrosine kinase inhibitor resistance 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
110 EGFR tyrosine kinase inhibitor resistance 💬
1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
111 EGFR tyrosine kinase inhibitor resistance 💬
1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
112 EGFR tyrosine kinase inhibitor resistance 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
113 EGFR tyrosine kinase inhibitor resistance 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
114 Endocrine resistance 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
115 Endocrine resistance 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
116 Endocrine resistance 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
117 Endocrine resistance 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
118 Endocrine resistance 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
119 Endocytosis 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
120 Endocytosis 💬
3件: FGFR2, FGFR3, PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
121 Endocytosis 💬
1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
122 Endocytosis 💬
1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
123 Endocytosis 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
124 Endometrial cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
125 Epithelial cell signaling in Helicobacter pylori infection 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
126 Epithelial cell signaling in Helicobacter pylori infection 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
127 ErbB signaling pathway 💬
1件: ABL1 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
128 ErbB signaling pathway 💬
1件: ABL1 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
129 ErbB signaling pathway 💬
2件: ABL1, SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
130 ErbB signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
131 ErbB signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
132 ErbB signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
133 ErbB signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
134 Estrogen signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
135 Estrogen signaling pathway 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
136 Fluid shear stress and atherosclerosis 💬
1件: KDR 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
137 Fluid shear stress and atherosclerosis 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
138 Fluid shear stress and atherosclerosis 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
139 Focal adhesion 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
140 Focal adhesion 💬
5件: FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
141 Focal adhesion 💬
1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
142 Focal adhesion 💬
1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
143 Focal adhesion 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
144 Focal adhesion 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
145 FoxO signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
146 GABAergic synapse 💬
3件: ABAT, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
147 GABAergic synapse 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
148 Gap junction 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
149 Gap junction 💬
1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
150 Gap junction 💬
1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
151 Gap junction 💬
2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
152 Gap junction 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
153 Gastric acid secretion 💬
1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
154 Gastric acid secretion 💬
1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
155 Gastric cancer 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
156 Gastric cancer 💬
1件: FGFR2 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
157 Gastric cancer 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
158 Gastric cancer 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
159 Gastric cancer 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
160 Glioma 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
161 Glioma 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
162 Glioma 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
163 Glioma 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
164 Glioma 💬
1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
165 Glioma 💬
1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
166 Glioma 💬
2件: PDGFRA, PDGFRB 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
167 GnRH secretion 💬
3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
168 GnRH signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
169 GnRH signaling pathway 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
170 Growth hormone synthesis, secretion and action 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
171 Growth hormone synthesis, secretion and action 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
172 Growth hormone synthesis, secretion and action 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
173 Growth hormone synthesis, secretion and action 💬
1件: SSTR2 💬 D00442 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
174 Growth hormone synthesis, secretion and action 💬
1件: SSTR2 💬 D06495 💬 Octreotide 7件: 67, 75, 84, 85, 89, 193, 227 💬
175 Hematopoietic cell lineage 💬
1件: KIT 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
176 Hematopoietic cell lineage 💬
1件: KIT 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
177 Hepatitis B 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
178 Hepatitis C 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
179 Hepatocellular carcinoma 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
180 Hepatocellular carcinoma 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
181 Hepatocellular carcinoma 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
182 Hepatocellular carcinoma 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
183 Herpes simplex virus 1 infection 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
184 Herpes simplex virus 1 infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
185 Herpes simplex virus 1 infection 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
186 Herpes simplex virus 1 infection 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
187 HIF-1 signaling pathway 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
188 HIF-1 signaling pathway 💬
1件: FLT1 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
189 HIF-1 signaling pathway 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
190 HIF-1 signaling pathway 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
191 HIF-1 signaling pathway 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
192 HIF-1 signaling pathway 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
193 Human cytomegalovirus infection 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
194 Human cytomegalovirus infection 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
195 Human cytomegalovirus infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
196 Human cytomegalovirus infection 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
197 Human cytomegalovirus infection 💬
1件: PDGFRA 💬 D01441 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
198 Human cytomegalovirus infection 💬
1件: PDGFRA 💬 D08066 💬 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162 💬
199 Human cytomegalovirus infection 💬
1件: PDGFRA 💬 D10481 💬 Nintedanib 5件: 51, 85, 89, 227, 228 💬
200 Human cytomegalovirus infection 💬
1件: PTGS2 💬 D00567 💬 Celecoxib 9件: 2, 3, 34, 46, 70, 89, 161, 171, 271 💬
201 Human cytomegalovirus infection 💬
1件: SRC 💬 D09664 💬 Saracatinib 3件: 6, 89, 272 💬
202 Human cytomegalovirus infection 💬
1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
203 Human immunodeficiency virus 1 infection 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
204 Human immunodeficiency virus 1 infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
205 Human immunodeficiency virus 1 infection 💬
1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
206 Human papillomavirus infection 💬
1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
207 Human papillomavirus infection 💬
1件: MTOR 💬 D02714 💬 Everolimus 9件: 34, 67, 89, 96, 137, 157, 158, 228, 277 💬
208 Human papillomavirus infection 💬
1件: MTOR 💬 D00753 💬 Sirolimus 40件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278,